Meghna Rao

In light of Rare Disease Day 2023, Yusuf Yazici, MD, and Peter Grayson, MD, discuss the various aspects of rare disease research and management, including the associated challenges in diagnosis, treatment, and patient care.

The American College of Rheumatology updated dosing and timing considerations for COVID-19 vaccines among patients with rheumatic and musculoskeletal diseases.

In light of Pain Awareness and Arthritis Awareness Month, Lawrence Edwards, MD, discusses the importance of addressing pain in patients with gout and the role of collaboration between clinical specialties during the management of painful gout flares.

The American College of Rheumatology updated COVID-19 vaccine clinical guidance to include recommendations regarding medication timing considerations during the management of patients with rheumatic and musculoskeletal diseases.

Rheumatologists and rheumatology providers across the United States have expressed their support and provided guidance for patients in light of Rheumatoid Arthritis Awareness Day this year.

Experts at the ACR Convergence conference discussed the use of Janus kinase inhibitors before/after biologics following methotrexate treatment failure in RA.

A first look at the sessions and events scheduled at the American College of Rheumatology (ACR) Convergence 2020, to be held online from November 5 to 9, 2020.

Researchers investigated the risk for SARS-CoV-2 infection in patients with rheumatic disease receiving vs not receiving hydroxychloroquine.

Study authors highlighted the challenges associated with the identification of published COVID-19 literature and suggested resources for rheumatologists and their patients.

There are significant differences in perceptions of prevalence, risk factors, and the management of RA-associated interstitial lung disease between rheumatologists and pulmonologists.

The American College of Rheumatology updated its COVID-19 guidance for the management of adult patients with rheumatic diseases.

Authors of this report assessed the role of iloprost in the management of COVID-19-related vasculopathy.

The American College of Rheumatology has issued a set of position statements for the use of telemedicine in the management of patients with rheumatic diseases.

Researchers assessed risk for inflammatory arthritis in patients with newly diagnosed hidradenitis suppurativa.

Researchers evaluated the association of psoriasis and psoriatic arthritis with inflammatory bowel disease and other gastrointestinal illnesses.

EULAR developed provisional recommendations for the management of rheumatic and musculoskeletal diseases during the COVID-19 pandemic.

Researchers evaluated the efficacy of low-dose denosumab for maintaining bone mineral density in postmenopausal women with osteoporosis.

In a study of lenabasum treatment in systemic sclerosis, researchers evaluated variability of immunosuppressive therapy by geographic region; includes Q&A with study lead author, Dr Christopher Denton.

Study leads Shilpa Venkatachalam, PhD, and Michael George, MD, discuss the highlights of a new initiative to track the effects of COVID-19 in autoimmune disorders.

Recent reports have indicated an association between a Kawasaki-like disease and COVID-19 in pediatric populations. Mary Beth Son, MD, of the Boston Children’s Hospital weighs in.

What are the top 3 things that rheumatologists need to know about vaccines in rheumatic diseases?

The American College of Rheumatology developed clinical guidance for rheumatology providers for the management of rheumatic diseases during the COVID-19 pandemic.

In this interview, Gregory P Nicholson, MD, discusses the applications of a novel joint preservation technology in glenohumeral osteoarthritis.

Investigators addressed the possibility of an ethical dilemma for rheumatologists in the event there is a hydroxychloroquine shortage during the COVID-19 pandemic.

The American College of Rheumatology released guiding principles for the allocation, use, and management of hydroxychloroquine during the COVID-19 pandemic.

In this interview, Jane E Salmon, MD, provides insight into the risk for COVID-19 in pregnant women with rheumatic diseases.

Drug reaction with eosinophilia and systemic symptoms (DReSS) with exposure to interleukin-1 or interleukin-6 inhibition may be linked to high fatality lung disease in systemic juvenile idiopathic arthritis.

Doug Roberts, MD, discusses the effect that the novel coronavirus could have in patients who are immunocompromised with rheumatic diseases.

In this case study presented at ACTRIMS 2020, researchers reported on data from a patient with Crohn disease and ankylosing spondylitis who developed autoimmune encephalitis while receiving infliximab.

The European League Against Rheumatism developed recommendations for the collection, analysis, and use of big data in rheumatic and musculoskeletal disorders.